Business Context and Reporting Period
Company: BioLineRx Ltd.
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2016
Business Overview: BioLineRx is a clinical-stage biopharmaceutical development company incorporated in Israel. The company focuses on identifying, in-licensing, and developing therapeutic candidates in oncology and immunology. Its pipeline includes the clinical-stage candidate BL-8040 (for AML and solid tumors), the near-clinical candidate AGI-134 (acquired via Agalimmune in March 2017), and the commercialized medical device BL-5010 (for benign skin lesions). The company has no internal sales force and relies on out-licensing and collaborations for commercialization.
Key Financial Metrics
| Metric (in thousands USD) | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research & Development Expenses | $(11,177) | $(11,489) |
| Sales & Marketing Expenses | $(1,352) | $(1,003) |
| General & Administrative Expenses | $(3,984) | $(3,704) |
| Operating Loss | $(16,513) | $(16,196) |
| Net Loss | $(15,841) | $(14,400) |
| Net Loss Per Share | $(0.28) | $(0.28) |
| Cash and Cash Equivalents | $2,469 | $5,544 |
| Short-term Bank Deposits | $33,154 | $42,119 |
| Total Liquidity (Cash + Deposits) | $35,623 | $47,663 |
| Total Assets | $38,939 | $51,302 |
| Total Liabilities | $3,912 | $3,692 |
| Shareholders' Equity | $35,027 | $47,610 |
Note: The company reported no material revenue for 2016. Expenses are primarily driven by clinical trials and development activities.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $1.4 million (9.3%) from 2015 to 2016, primarily due to a decrease in non-operating income (fair value adjustments on warrant liabilities) and a slight increase in operating expenses.
- Liquidity Decline: Total cash and short-term investments decreased by approximately $12 million year-over-year, driven by operating cash outflows of $14.5 million and reduced investment income.
- Expense Fluctuations:
- R&D: Decreased slightly by $0.3 million due to reduced spending on the terminated BL-7010 project, partially offset by increased spending on new projects.
- Sales & Marketing: Increased by $0.4 million (40%) due to consultancy services related to BL-8040 and new projects.
- G&A: Increased by $0.3 million due to one-time salary-related payments and higher professional fees.
- Non-Operating Income: Decreased significantly from $1.4 million in 2015 to $0.2 million in 2016, largely attributed to fluctuations in the company's share price affecting the fair value of warrant liabilities.
Guidance, Outlook, and Risks
Outlook and Capital Resources:
- Management believes existing cash and investment balances ($35.6 million as of Dec 31, 2016) are sufficient to fund operations into 2019.
- The company expects to continue incurring significant operating losses as it advances clinical trials for BL-8040 and AGI-134.
- Future funding may be required through equity offerings, debt financing, or milestone payments from collaborators (e.g., Omega Pharma, Novartis, Merck, Genentech).
Key Risks and Contingencies:
- Clinical Trial Failure: High risk that therapeutic candidates (BL-8040, AGI-134) may fail to demonstrate safety or efficacy in clinical trials, preventing regulatory approval.
- Regulatory Approval: Dependence on FDA and foreign regulatory approvals; delays or rejections would materially impact the business.
- Liquidity: If additional financing is not available on acceptable terms, the company may need to delay, reduce, or eliminate research programs.
- Intellectual Property: Reliance on in-licensed technology; failure to meet milestones or pay royalties could result in loss of rights to key candidates.
- Geopolitical Risk: Operations are based in Israel; regional instability or military conflict could disrupt operations or require employee call-ups.
- PFIC Status: The company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could have adverse tax consequences for U.S. investors.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $35.6 million cash balance against projected burn rates for 2017-2019, considering the high cost of Phase 2 and Phase 3 trials.
- BL-8040 Clinical Data: Review the detailed results of the Phase 2a trial for relapsed/refractory AML (38-41% composite complete remission rate) and monitor upcoming Phase 2b consolidation trial results expected in 2018-2019.
- Collaboration Milestones: Track progress and potential revenue triggers from agreements with Omega Pharma (BL-5010), Novartis, Merck (MSD), and Genentech.
- Agalimmune Integration: Assess the status of the AGI-134 program following the March 2017 acquisition and the terms of the reversionary option held by selling shareholders.
- Warrant Liability: Monitor the fair value adjustments of outstanding warrants, as these significantly impact non-operating income/loss and net loss figures.
- Israeli Government Grants: Review obligations related to the Israel Innovation Authority (IIA) and potential contingent liabilities regarding technology transfer or manufacturing outside Israel.